The Latest Breaking News from Cantor

With rate cuts on the horizon, here are three stocks poised to benefit, according to analysts.

MicroStrategy is a good stock to own if you are bullish about Bitcoin's long-term prospects. For investors with a higher risk profile, the MSTX ETF might also seem attractive.

Pablo Zuanic from Cantor Fitzgerald offered an industry update, covering cannabis pricing in Pennsylvania and Florida based on retailers’ menus. “Think of this report as 'food for thought' - we are not adjusting estimates or our investment views,” Zuanic said.

Anshu Jain, Cantor Fitzgerald’s president who was known for his time leading Deutsche Bank traders into the lender’s investment banking heights, died five years after being diagnosed with duodenal cancer. He was 59.

In perhaps a sign that incremental progress on federal cannabis reform is afoot, some Wall Street analysts are increasingly coming around on the idea that reform can happen this year. Cantor Fitzgerald analyst Pablo Zuanic, a noted skeptic on SAFE Banking, now believes the legislation has a real chance of…

Celldex Therapeutics Inc's (NASDAQ:CLDX) shares closed almost 16% down on Friday after releasing Phase 1b study data of barzolvolimab. Cantor says the main reason for stock being down is the four patient adverse events on the generally transient, asymptomatic, and mild neutrophil decreases, noting a single Grade 3 case. One patient had values…

Cantor Fitzgerald has upgraded Aurora Cannabis Inc (NASDAQ: ACB) to Overweight from Neutral

Cantor assumes coverage of RAPT Therapeutics Inc (NASDAQ:RAPT) with an Overweight rating and a price target of $44 (vs. $58 previously).  The analyst says the company's RPT193 (lead inflammation drug) could be a $3 billion drug in just atopic dermatitis (AD) indication, as it expects AD to outperform psoriasis. Cantor suggests that ‘193 is…

Cantor initiated coverage on Lyra Therapeutics Inc (NASDAQ:LYRA) with an Overweight rating and a price target of $15 (166% upside).  According to the analyst, Lyra product pipeline's peak sales potential is under-appreciated, and it expects upward earnings estimate revisions to potentially move LYRA's stock higher. LYRA is well-positioned with a portfolio of products to…